Antibacterial-induced hepatotoxicity. Incidence, prevention and management

Drug Safety

Volumn 15, Issue 1, 1996, Pages 79-85

  George, D Keith ^a   Crawford, Darrell H G ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; CLOXACILLIN; DICLOXACILLIN; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; MACROLIDE; MINOCYCLINE; NITROFURAN DERIVATIVE; NITROFURANTOIN; NORFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TROLEANDOMYCIN;

ACUTE HEPATITIS; CHOLESTATIC HEPATITIS; CHRONIC ACTIVE HEPATITIS; DRUG FATALITY; FATTY LIVER; FEMALE; GRANULOMATOUS HEPATITIS; HUMAN; INCIDENCE; LIVER TOXICITY; LIVER TRANSPLANTATION; MALE; MORBIDITY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE;

EID: 0029885503     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615010-00007     Document Type: Review

References (56)

1. Domecq C, Naranjo CA, Ruiz I, et al. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 1980; 18: 362-6
2. Zimmerman HJ, Maddley WC. Drug induced hepatotoxicity. In: Schiff L, Schiff ER, editors. Diseases of the liver, 6th ed. Philadelphia: JP Lipincott, 1987
3. Farrell GC. Drug induced liver disease. Edinburgh: Churchill Livingstone, 1994
4. Lumley CE, Walker SR, Hall GC, et al. The under reporting of adverse drug reactions seen in general practice. Pharm Med 1986; 1: 205-12
5. Hallas H, Gram LF, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992; 33: 61-8
6. Derby LE, Jick H, Henry DA, et al. Cholestatic hepatitis associated with flucloxacillin. Med J Aust 1993; 158: 596-600
7. Derby LE, Jick H, Henry DA, et al. Erythromycin-associated cholestatic hepatitis. Med J Aust 1993; 158: 600-2
8. Carson JL, Strom BL, Duff A, et al. Acute liver disease associated with erythromycins, sulfonamides and tetracyclines. Ann Intern Med 1993; 119: 576-83
9. Beard K, Belic L, Aselton P, et al. Outpatient drug-induced parenchymal liver disease requiring hospitalization. J Clin Pharmacol 1986; 26: 633-7
10. Jick H, Walker AM, Porter J. Drug-induced liver disease. J Clin Pharmacol 1981; 21: 359-64
11. Miller RR. Hospital admissions due to adverse drug reactions: a report from the Boston Collaborative Drug Surveillance Programme. Arch Intern Med 1974; 134: 219-23
12. Friis H, Andreason PB. Drug-induced hepatic injury: an analysis of 1100 cases reported to The Danish Committee on Adverse Drug Reactions between 1978 and 1987. J Intern Med 1992; 232: 133-8
13. Onate J, Montejo M, Aguirrebengoa K, et al. Hepatotoxicity associated with penicillin V therapy. Clin Infect Dis 1995; 20: 474-5
14. Davies MH, Harrison RF, Elias E, et al. Antibiotic associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol 1994; 20: 112-6
15. Cavanzo FJ, Garcia CF, Botero RC. Chronic cholestasis paucity of bile ducts, red cell aplasia and the Stevens-Johnson syndrome: an ampicillin-associated case. Gastroenterology 1990; 99: 854-6
16. Anderson CS, Nicholls J, Rowland R, et al. Hepatic granulomas: a 15 year-experience in the Royal Adelaide Hospital. Med J Aust 1988; 148: 71-4
17. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 1992; 33: 368-71
18. Wong FS, Ryan J, Dabkowski, et al. Augmentin-induced jaundice. Med J Aust 1991; 154: 698-701
19. Reddy KR, Brillant P and Schiff ER. Amoxycillin-clavulanate potassium-associated cholestasis. Gastroenterology 1989; 96: 1135-41
20. Hautekeete ML, Brenard R, Horsmans, et al. Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol 1995; 22:71-77
21. Kando JC, Yonkers AK, Cole OJ. Gender as a risk factor for adverse events to medications. Drugs 1995; 50: 1-6
22. Haboir A, Walewska-Zielecka B, Butruck E, et al. Hepatocellular-cholestatic liver injury due to amoxycillin-clavulanic acid combination. Clin Investig 1994; 72: 616-8
23. Silvan C, Fort E, Levillian P, et al. Granulomatous hepatitis due to combination of amoxycillin and clavulanic acid. Dig Dis Sci 1992; 32: 150-2
24. Hebbard GS, Smith KGC, Gibson PR, et al. Augmentin-induced jaundice with a fatal outcome. Med J Aust 1992; 156: 285-6
25. Devereaux BM, Crawford DHG, Purcell P, et al. Flucloxacillin associated cholestatic hepatitis. Eur J Clin Pharmacol 1995; 49: 81-5
26. Olsson R, Wiholm BE, Sand C, et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992; 15: 154-61
27. Fairley CK, McNeil JJ, Desmond P, et al. Risk factors for development of flucloxacillin associated jaundice. BMJ 1993; 306: 233-5
28. Pollock AA, Berger SA, Simberkoff MS, et al. Hepatitis associated with high-dose oxacillin therapy. Arch Intern Med 1978; 138: 915-7
29. Dismukes WE. Oxacillin-induced hepatic dysfunction. JAMA 1973; 226: 861-3
30. Verghese A, Roberson D, Kalbfleisch JH, et al. Randomized comparative study of cefoxime versus cephalexin in acute bacterial exacerbations of chronic bronchitis. Antimicrob Agents Chemother 1990; 34: 1041-4
31. Christenson JC, Swenson E, Gooch WM, et al. Comparative efficiency and safety of cefprozil and cefaclor in the treatment of acute Group A-haemolytic streptococcal pharyngitis. Antimicrob Agents Chemother 1991; 35: 1127-30
32. Wesphal JF, Vetter D and Brogard JM. Hepatic side-effects of antibiotics. J Antimicrob Chemother 1994; 33: 387-401
33. Tanner AR. Hepatic cholestasis induced by trimethoprim. BMJ 1986; 293: 1072-3
34. Braun P. Hepatotoxicity of Erythromycin. J Infect Dis 1969; 119: 300-6
35. Gholsonn CF, Warren GH. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med 1990; 150: 215-216
36. Ticktin HE, Zimmerman HJ. Hepatic dysfunction and jaundice in patients receiving triacetylolearnomycin. N Engl J Med 1962; 267: 264-8
37. Periti P, Mazzei T, Mini E, et al. Adverse effects of macrolide antibacterials. Drug Saf 1993; 9 (5): 346-64
38. Schultz J, Adamson JS, Workman WW, et al. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 1963; 269: 999-1004
39. Dowling HF, Lepper MH. Hepatic reactions to tetracycline. JAMA 1964; 188: 307-9
40. Peters RL, Edmondson HA, Mikkelson WP, et al. Tetracycline-induced fatty liver in nonpregnant patient: a report of six cases. Am J Surg 1967; 113: 622-32
41. Burette A, Finet C, Prigogine T, et al. Acute hepatic injury associated with minocycline. Arch Intern Med 1984; 144: 1491-2
42. Gough A, Chapman S, Wagstaff K, et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996; 312: 169-72
43. Hunt CM, Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 1994; 107: 1844-7
44. Halkin H. Adverse effects of the fluroquinolones. Rev Infect Dis 1988; 10: Suppl. 1: 5258-61
45. Corrado ML, Struble WE, Peter C, et al. Norfloxacin: review of safety studies. Am J Med 1987; 82: Suppl 6B: 22-6
46. Lopez-Navidad A, Domingo P, Cadafalch J, et al. Norfloxacin-induced hepatotoxicity. J Hepatol 1990; 11: 277-8
47. Villeneuve JP, Davies C, Cote J. Suspectedciprofloxacin-induced hepatotoxicity. Ann Pharmacotherapy 1995; 29: 257-9
48. Stricker BH, Blok APR, Claas FHJ, et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988; 8: 599-606
49. Mollison LC, Angus P, Richards M, et al. Hepatitis due to nitorfurantoin. Med J Aust 1992; 156: 347-9
50. D'Arcy PF. Nitrofurantoin. Drug Intell Clin Pharm 1985; 19: 540-7
51. Iwarsson S, Lindberg J, Lundin P. Nitrofurantoin-induced chronic liver disease: clinical course and outcome of five cases. Scand J Gastroenterol 1979; 14: 497-502
52. Gordin FM, Simon GL, Wofsy CB, et al. Adverse reactions to trimethoprim-sulfanethoxazole in patients with acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 495-9
53. Peters BS, Carlin E, Weston RJ, et al. Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection Drug Saf 1994; 10 (6): 439-54
54. Benichou C. Criteria for drug-induced liver disorders: report of an International Consensus Meeting. J Hepatol 1990; 11: 272-6
55. Danan G. Consensus meetings on: causality assessment of drug-induced liver injury. J Hepatol 1988; 7: 132-6
56. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis 1986; 6: 97-106